Adenocarcinoma in situ of the uterine cervix remains a diagnostic challenge in a small proportion of cases. This suggests a need for biomarker that may be of help in establishing the diagnosis. The aim of this study was to evaluate the potential of insulin-like growth factor-II mRNA-binding protein 3 and cyclin-dependent kinase inhibitor p16
INK4a
Adenocarcinoma in situ of the uterine cervix is presently thought to be the precursor lesion of invasive adenocarcinoma, and its incidence is increasing in frequency. 1, 2 The majority of the adenocarcinoma in situ cases are first diagnosed on cervical biopsies, and subsequently confirmed by cold knife cone excision or hysterectomy. Although detailed diagnostic morphologic criteria for adenocarcinoma in situ including nuclear atypia, stratification, high mitotic rate, and increased apoptotic bodies 1, 2 have been established, there are a number of cases which present a diagnostic challenge to pathologists in distinguishing adenocarcinoma in situ from benign mimics, such as tubal metaplasia, reactive changes, and other benign processes, particularly in small biopsy samples. At present, ancillary technologies, molecular or immunohistochemical that may aid in making this important distinction are very limited. Here, we present our findings on the role of IMP3 in the diagnosis of adenocarcinoma in situ.
Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) known in previous publications as L523S or KOC (K-homologous domain containing protein overexpressed in cancer), 3, 4 is a newly identified oncofetal RNA-binding protein that binds to mRNAs such as insulin-like growth factor-II (IGF-II) transcripts. IMP3 is expressed during embryogenesis but not in most adult tissues. 5, 6 By using cDNA library subtraction and large-scale DNA screening techniques, the IMP3 gene has been found to be expressed in pancreatic and lung carcinomas. 7, 8 The IMP3 protein consists of 580 amino-acid residues and is encoded by a 4350-nucleotide mRNA transcript. The IMP3 gene is located on chromosome 7p11.5. A monoclonal antibody specific for IMP3 has been used successfully with routine immunohistochemical methods to study overexpression of IMP3 protein in a number of malignant tumors. 3, 4 Recently, it has been demonstrated that IMP3 expression is an independent prognostic factor for renal cell carcinoma. 9 Cyclin-dependent kinase (CDK) inhibitor p16
protein is a member of the INK4 family of cell cycle regulatory proteins and specifically inhibits the formation of cyclin D1-CDK4/6 complexes [10] [11] [12] which control the activity of retinoblastoma tumorsuppressor protein pRb by phosphorylation. 13 Recent studies have revealed that p16
INK4a expression is influenced by the status of pRb expression by a negative feedback loop between pRb and p16
INK4a .
Overexpression of p16
INK4a has been demonstrated in cervical squamous and glandular neoplasia due to functional inactivation of pRb by human papillomavirus (HPV) oncoprotein E7. Therefore, p16
INK4a is currently considered a biomarker to identify intraepithelial squamous and glandular lesions on both cervical biopsies and cytology specimens.
The primary aim of this study was to evaluate the expression of IMP3 and p16
INK4a in adenocarcinoma in situ as well as benign endocervical glands by immunohistochemical techniques with the secondary aim of assessing a possible role of IMP3 in the diagnosis of adenocarcinoma in situ.
Materials and methods

Case Selection
Forty consecutive patients with adenocarcinoma in situ of the uterine cervix were identified from the files of the Department of Pathology of the UMass Memorial Medical Center from January 1997 to April 2006. The specimens included six cervical biopsies, 25 cold-knife cone excisions, eight LEEP (loop electrosurgical excision procedure) excisions and five hysterectomies. Four (10%) of the 40 patients had both their initial biopsy or cone excision and subsequent cone excision or hysterectomy procedures done at UMass Memorial Medical Center, providing a total of 44 samples available for this study. The diagnosis of adenocarcinoma in situ was confirmed according to the published diagnostic criteria.
1,2 A control group was derived from 23 patients who underwent hysterectomy at UMass Memorial Medical Center in 2004 for benign uterine lesions including leiomyomas, adenomyosis, and endometrial polyps. All 23 control patients showed normal endocervical glandular epithelium. Focal tubal metaplasia in the endocervix was identified in 19 of the 23 control cases. No squamous intraepithelial lesions or other endocervical glandular abnormalities were found among these 23 patients.
Immunohistochemical Study
Immunohistochemical stains were performed as described previously. 4, 9 Briefly, 5-mm tissue sections from selected blocks were cut, deparaffinized, washed, immersed in citrate buffer (0.01 M, pH 6.0), and underwent microwave (770 W, 14 min) antigen retrieval. The slides were cooled, rinsed with PBS (three rinses, 5 min each), and stained on a DAKO Autostainer (DAKO Corporation, Carpinteria, CA, USA) at room temperature. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide, and the slides were rinsed and treated with a blocking protein (Chemmate, Ventana, and Tuscon, AZ, USA) to prevent non-specific staining. The sections were then incubated with L523S, a mouse monoclonal antibody specific for IMP3 (2 mg/ml; Corixa Corporation, Seattle, WA, USA) for 45 min, or with p16
INK4a mouse monoclonal antibody (clone: 6H12; dilution: 1:100; Novocastra Laboratories, UK) for 30 min. Following brief buffer washes, the sections were treated with a cocktail of biotinylated anti-rabbit IgG and anti-mouse IgG/IgM (Chemmate) for 30 min, washed, and incubated with avidin/biotin/peroxidase complex (Chemmate) for 30 min. The sections were rinsed, developed with diaminobenzidine (Chemmate) and hydrogen peroxide (10 min), rinsed with tap water, and counterstained with hematoxylin.
Representative sections of pancreatic carcinoma were used as positive controls for IMP3 expression and sections of high-grade uterine cervical squamous dysplasia were used as positive control for p16 INK4a . Negative controls were performed by replacing the primary antibody with nonimmune IgG. A positive stain for p16
INK4a was defined as brown stain seen in the cytoplasm and/or nucleus. The percentage of adenocarcinoma in situ, tubal metaplasia or normal endocervical glandular epithelium that was positive for either IMP3 or p16 INK4a was assessed. The intensity of the staining was evaluated as weak, intermediate, or strong.
Results
Clinicopathologic Features
The patient age ranged from 23-to 56-year-old, with 16 from 20 to 29, 15 from 30 to 39, 7 from 40 to 49, and 2 from 50 to 59 age groups. The mean age was 32 years. Thirteen of 44 specimens had concurrent high-grade squamous intraepithelial lesions. Four IMP3 as a biomarker for adenocarcinoma in situ C Li et al patients had invasive adenocarcinoma and two had invasive squamous cell carcinoma. The age of the 23 control patients with hysterectomy for benign uterine lesions ranged from 34 to 58 years. All 23 cases had Leiomyomas. Additionally, 13 cases also had adenomyosis, and four had endometrial polyps.
Immunohistochemical Findings
IMP3 expression
Forty-one of 44 samples with adenocarcinoma in situ (93%) showed cytoplasmic staining for IMP3 ( Figure 1 ). As indicated in Table 1 , among the adenocarcinoma in situ cases, 29 showed positive Table 2 , the staining intensity was intermediate in seven cases, and strong in the remainder. Two out of 23 cases of normal endocervix showed weak p16
INK4a staining in o5% of the glandular epithelium, and 21 cases were negative. Fourteen out of 19 cases with tubal metaplasia showed both nuclear and cytoplasmic p16
INK4a positivity in more than 50% of the tubal metaplastic epithelium, and remaining five cases demonstrated positive p16
INK4a stain in 20% or less of the tubal metaplastic epithelium. Stain intensity for p16
INK4a in tubal metaplastic epithelium was strong in four cases, intermediate in seven cases, and weak in eight cases. Thirteen concurrent highgrade squamous intraepithelial lesions and two invasive squamous cell carcinoma cases demonstrated diffuse and strong to intermediate p16 
Discussion
The IMP3 gene was initially identified in pancreatic carcinomas in 1996, 7 and subsequently cloned in 1997.
14 IMP3 together with IMP1 and IMP2, three members of human IGF-II mRNA binding protein family were first purified from the human rhabdomyosarcoma cell line RD in 1999. 5 They have been shown to play an important role in the binding, trafficking, and stabilization of the fetal subtype of IGF-II mRNA during embryogenesis. 5, 15 As a result, IGF-II expression is indirectly regulated by IMP3 and other proteins in the IMP family. IGF-II overexpression has been implicated in the pathogenesis of the tumors in multiple organ systems seen in the Beckwith-Wiedemann syndrome, and the development of breast and liver tumors in transgenic mouse models as well as hepatocellular carcinoma in viral hepatitis mouse models. [16] [17] [18] Therefore, it is hypothesized that IMP family members are involved in carcinogenesis by stabilizing IGF-II mRNA. However, the IMP proteins also bind and affect other mRNAs and this may also influence the malignant potential of cells.
In this study, we have shown that IMP3 is highly expressed in adenocarcinoma in situ of the uterine cervix as compared to benign endocervical glands. Previous data has shown that IMP3 expression is not tumor specific. 3, 4, 9 It is more likely that IMP3 is a marker of malignancy. IMP3 overexpression has been reported in carcinomas of the stomach, colon, 19 If IMP3 is a marker of malignancy, then expression of IMP3 in adenocarcinoma in situ as demonstrated in this study provides molecular evidence that adenocarcinoma in situ is malignant and may represent the precursor lesion for invasive cervical adenocarcinoma.
A large body of epidemiologic and molecular data has shown that high-risk types of the human papillomavirus (HPV) are the etiologic agents for most cases of endocervical glandular neoplasia. 20 
